NCT06554639View on ClinicalTrials.gov

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

August 5, 2024

Study Completion Date

August 29, 2024

Conditions
Prostatic Neoplasms
Interventions
DRUG

MK-5684

Administered via oral tablet per dosing regimen.

DRUG

Prednisone

Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.

DRUG

Fludrocortisone acetate

Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.

DRUG

Diltiazem hydrocholoride

Administered at a dose of 240 mg per dosing regimen via oral capsule (extended-release).

Trial Locations (1)

85283

Celerion ( Site 0001), Tempe

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06554639 - A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011) | Biotech Hunter | Biotech Hunter